Insight, China's Pharmaceutical Industry

Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment

Suzhou HemaCell Therapeutics, a platelet‑regeneration‑focused cell‑therapy developer, announced that the Center for Drug Evaluation (CDE)...

Company

Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone

Fineline Cube Aug 29, 2025

Everest Medicines Limited (HKG: 1952) released unaudited interim financial results for the six months ended...

Company

Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains

Fineline Cube Aug 29, 2025

Luye Pharma Group Ltd. (HKG: 2186) on Aug. 28, 2025 released its financial performance for...

Company

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge

Fineline Cube Aug 29, 2025

Shanghai Pharmaceutical Holding Co., Ltd. (SHA: 601607, HKG: 2607) on Aug. 28, 2025 announced its...

Company Deals

Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025

Fineline Cube Aug 29, 2025

Zennova Pharmaceuticals Group and Rapafusyn Pharmaceuticals on Aug. 28, 2025 announced a strategic collaboration to...

Company Drug

Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China

Fineline Cube Aug 29, 2025

In a joint announcement, Boehringer Ingelheim (BI) and Sino Biopharmaceutical Limited (HKG: 1177) confirmed that the...

Company

Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion

Fineline Cube Aug 28, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) on Aug. 28, 2025 released its semi‑annual financial results for...

Policy / Regulatory

NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed

Fineline Cube Aug 28, 2025

The National Healthcare Security Administration (NHSA) on Aug. 28, 2025 announced the formal review outcomes...

Company

HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics

Fineline Cube Aug 28, 2025

Harbour BioMed (HKG: 2142) on Aug. 27, 20025 released its first‑half 2025 financial results, reporting...

Company Drug

Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia

Fineline Cube Aug 28, 2025

Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced that its RYJUSEA (atropine sulfate hydrate) has...

Company Deals

Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China

Fineline Cube Aug 28, 2025

Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) announced that it has entered into a license...

Company Drug

RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial

Fineline Cube Aug 28, 2025

China‑based RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) on Aug, 27, 2025announced that its first‑in‑class BLyS/APRIL...

Company Deals

ImmuneOnco Secures $5 M Milestone from Instil Bio, Strengthening Axion Bio Collaboration

Fineline Cube Aug 28, 2025

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) on Aug 28, 2025 announced the receipt of...

Company

Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3‑Year Profit Trend

Fineline Cube Aug 28, 2025

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...

Others

HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge

Fineline Cube Aug 28, 2025

China-based HitGen Inc. (SHA: 688222) on Aug 27, 2025 released its semi‑annual financial results for...

Company Drug

Changchun High Files GenSci134 Clinical Trial for Growth Hormone Deficiency

Fineline Cube Aug 27, 2025

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) on Aug 27, 2025 disclosed...

Company Deals

Fosun Pharma Grants Sitala Global License for FXS6837 – Up to $190 M Milestones

Fineline Cube Aug 27, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement...

Company Drug

Regeneron’s Cemdisiran Beats Key Milestones in Phase III gMG Trial

Fineline Cube Aug 27, 2025

US-based Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Aug 27, 2025 disclosed that its investigational monotherapy, cemdisiran,...

Company Drug

Gilead’s Yeytuo Gains EU Marketing Authorization for Twice‑Yearly HIV‑1 PrEP

Fineline Cube Aug 27, 2025

European Commission Grant – On 26 Aug 2025 Gilead Sciences (NASDAQ: GILD) announced that the European Commission...

Company Deals

TYK Medicines Secures Exclusive Distribution of TY‑9591 in Mainland China

Fineline Cube Aug 27, 2025

China-based TYK Medicines, Inc. (HKG: 2410) announced on August 26, 2025, that it has entered...

Insight, China's Pharmaceutical Industry

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Suzhou HemaCell Receives NMPA IND Approval for First‑In‑Class Megakaryocyte Injection – Thrombocytopenia Treatment

Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone

Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge

Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025

Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China

Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion

NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed

HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics

Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia

Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China

RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial

ImmuneOnco Secures $5 M Milestone from Instil Bio, Strengthening Axion Bio Collaboration

Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3‑Year Profit Trend

HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge

Changchun High Files GenSci134 Clinical Trial for Growth Hormone Deficiency

Fosun Pharma Grants Sitala Global License for FXS6837 – Up to $190 M Milestones

Regeneron’s Cemdisiran Beats Key Milestones in Phase III gMG Trial

Gilead’s Yeytuo Gains EU Marketing Authorization for Twice‑Yearly HIV‑1 PrEP

TYK Medicines Secures Exclusive Distribution of TY‑9591 in Mainland China

You Missed

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors